Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination herbal product** consisting of standardized extracts of **black cohosh** (*Actaea racemosa* L.) and **rhodiola rosea** (*Rhodiola rosea* L.) root. It has been clinically formulated and investigated for the relief of menopausal symptoms. Mechanistically, black cohosh is thought to modulate serotonin receptors and act as a selective estrogen receptor modulator, contributing to relief from vasomotor and neuropsychological menopausal symptoms. Rhodiola rosea is an adaptogen that influences neurotransmitter levels (including serotonin, dopamine, and norepinephrine) and exerts anti-fatigue, anti-stress, and neuroprotective effects. In clinical trials, this combination significantly reduced menopausal symptom scores (e.g., Kupperman Menopausal Index, Menopause Rating Scale) and improved quality of life, particularly emotional and physical health, in women with moderate menopausal symptoms. The combination has demonstrated a favorable safety profile, with adverse event incidence comparable to or less than placebo, and efficacy superior to black cohosh alone, especially in psychological symptoms and overall quality of life[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on black cohosh + rhodiola rosea.